Total amount: € 0,00
Official Journal of the Italian Society of Thoracic Endoscopy
Indexed/Abstracted in: EMBASE, Scopus
Online ISSN 1827-1723
Zannini G., Masotti A., Bottrighi P., Rossi A., Rossi M., Settino A., Ferrari P.
Background. Patients suffering from chronic bronchitis experience periodic episodes of infective re-exacerbation. This study compared the microbiological and clinical efficacy of lomefloxacin vs ciprofloxacin in antibiotic treatment of the re-exacerbation of chronic bronchitis.
Methods. The study involved 5 Centres of Pneumology and used a randomised prospective open experimental design, comparing lomefloxacin (Group L) 400 mg/die and ciprofloxacin (Group C) 500 mg x 2/die, duration of treatment 7-10 days, follow-up of up to one month after treatment. The patients enrolled in the study met the following criteria: clinical signs of the re-exacerbation of chronic bronchitis and microbiological identification of the pathogen. Clinical and microbiological parameters were evaluated at the following stages: before treatment, 3-4 days during treatment, at the end of treatment and one month after treatment.
Results. A complete or partial resolution of signs and symptoms was observed at the end of treatment in 93% of Group L and 90% of Group C, with eradication of the pathogen isolated on enrolment in 73% of Group L and 72% of Group C.
Conclusions. Both antibiotics were equally efficient in resolving the clinical picture and eradicating the pathogens responsible for the re-exacerbation of chronic bronchitis. No collateral effects were noted in relation to the treatment. A single dose of lomefloxacin may improve compliance in elderly patients who are often receiving concomitant chronic treatment.